Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

A new Alzheimer’s drug, lecanemab, may slow disease progression and offer patients up to four extra years of stable health.

What the science says about lecanemab On Friday, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee met to discuss the results from a confirmatory Phase 3 study on ...

Lecanemab, the disease-modifying drug which can slow down the progression of Alzheimer’s disease, is set to be one of the most sought-after medications in the country after UK regulators ...

Lecanemab's price may pose another barrier, even with insurance coverage. The drug's maker, Eisai, expects the medicine alone to cost $26,500 a year. Diagnostic and follow-up tests will add to that.

In a large study, experimental drug lecanemab was able to slow down Alzheimer's, but not stop it. Some researchers think the drug will become the first to help many patients; others have questions.

A Japanese health ministry panel on Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and US industry peer Biogen Inc., by 15 ...